Transactions

Transactions

  • Lyft, Inc. offers ridesharing and peer-to-peer transportation services via its mobile application.
  • Quarton, A Cowen Company advised Waterland Private Equity and other shareholders on the sale of shares in Eye Clinic Holding GmbH, owner of Zentrum Gesundheit GmbH, to NORD Holding Unternehmensbeteiligungsgesellschaft mbH and Deutsche Mittelstandsholding
  • Blueprint Medicines is a biopharmaceutical company focused on developing therapies for genomically-defined diseases driven by abnormal kinase activation.
  • MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases
  • Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using proprietary PRINT technology to transform the lives of patients.
  • Dermira is a biopharmaceutical company that identifies, develops, and commercializes novel therapies to treat dermatologic diseases with significant unmet need
  • NanoString Technologies provides life science tools for translational research and molecular diagnostic products.
  • Sound Seal is a leading designer and manufacturer of essential acoustical noise control products that solve noise problems encountered in nearly every industry.
  • GDS Holdings Limited is a leading developer and operator of high-performance data centers in China.
  • Rimini Street, Inc. is a global provider of enterprise software support products and services, and the leading independent software support provider for Oracle and SAP products,
  • Dialog is recognized as a leading semiconductor supplier in low-power technologies and has established itself as a leader for Bluetooth low energy SoCís and Configurable Mixed-Signal ICs (CMICs) across IoT applications.
  • Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3.
1 2 3 4 ...93 Next